Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
Among the differentiated forms of thyroid cancer, the least favorable clinical prognosis is observed in radioiodine-refractory differentiated thyroid cancer. The next step in the treatment of such patients is effective and potential toxicity multi-kinase inhibitors. Often, patients with refractory r...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-11-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/673 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401724859580416 |
|---|---|
| author | P. O. Rumyantsev E. V. Borodavina S. I. Kutukova E. B. Vasilyeva |
| author_facet | P. O. Rumyantsev E. V. Borodavina S. I. Kutukova E. B. Vasilyeva |
| author_sort | P. O. Rumyantsev |
| collection | DOAJ |
| description | Among the differentiated forms of thyroid cancer, the least favorable clinical prognosis is observed in radioiodine-refractory differentiated thyroid cancer. The next step in the treatment of such patients is effective and potential toxicity multi-kinase inhibitors. Often, patients with refractory radioiodine thyroid cancer have a high tumor burden, various symptoms and comorbidity; therefore, clinicians may decide to initiate therapy at a reduced starting dose. In a randomized clinical multicenter study 211 higher objective response rate at 24th weeks were observed in the group of patients receiving lenvatinib at a dose of 24 mg per day compared with patients receiving Lenvatinib at a dose of 18 mg per day, while the difference in the incidence of serious adverse events grade 3–4 (SAE) at the 24th week of treatment were insignificant. Real clinical practice differs from randomized clinical trials regarding to the population of patients, their selection for treatment, adherence to drug dosage regimens, follow-ups, etc. In this paper, we analyzed the world and domestic clinical practice of the treatment of radioiod-refractory thyroid cancer and assessed the effect of the starting dose of lenvatinib and the duration of breaks in its administration on the effectiveness and safety of therapy. |
| format | Article |
| id | doaj-art-45e2449d36bb4bc1b0404b98b1573d1e |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2021-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-45e2449d36bb4bc1b0404b98b1573d1e2025-08-20T03:37:43ZrusABV-pressОпухоли головы и шеи2222-14682411-46342021-11-01113475510.17650/2222-1468-2021-11-3-47-55455Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practiceP. O. Rumyantsev0E. V. Borodavina1S. I. Kutukova2E. B. Vasilyeva3National Medical Research Center of Endocrinology, Ministry of Health of RussiaA. Tsyb Medical Radiological Research Center – branch of the National Medical Radiological Research Center, Ministry of Health of RussiaI.P. Pavlov First Saint-Petersburg State Medical University; City Clinical Oncological DispensaryChelyabinsk Regional Clinical Center of Oncology and Nuclear MedicineAmong the differentiated forms of thyroid cancer, the least favorable clinical prognosis is observed in radioiodine-refractory differentiated thyroid cancer. The next step in the treatment of such patients is effective and potential toxicity multi-kinase inhibitors. Often, patients with refractory radioiodine thyroid cancer have a high tumor burden, various symptoms and comorbidity; therefore, clinicians may decide to initiate therapy at a reduced starting dose. In a randomized clinical multicenter study 211 higher objective response rate at 24th weeks were observed in the group of patients receiving lenvatinib at a dose of 24 mg per day compared with patients receiving Lenvatinib at a dose of 18 mg per day, while the difference in the incidence of serious adverse events grade 3–4 (SAE) at the 24th week of treatment were insignificant. Real clinical practice differs from randomized clinical trials regarding to the population of patients, their selection for treatment, adherence to drug dosage regimens, follow-ups, etc. In this paper, we analyzed the world and domestic clinical practice of the treatment of radioiod-refractory thyroid cancer and assessed the effect of the starting dose of lenvatinib and the duration of breaks in its administration on the effectiveness and safety of therapy.https://ogsh.abvpress.ru/jour/article/view/673radioiodine refractory thyroid cancerlenvatinibstarting doseinitial doseclinical practice |
| spellingShingle | P. O. Rumyantsev E. V. Borodavina S. I. Kutukova E. B. Vasilyeva Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice Опухоли головы и шеи radioiodine refractory thyroid cancer lenvatinib starting dose initial dose clinical practice |
| title | Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice |
| title_full | Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice |
| title_fullStr | Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice |
| title_full_unstemmed | Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice |
| title_short | Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice |
| title_sort | personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice |
| topic | radioiodine refractory thyroid cancer lenvatinib starting dose initial dose clinical practice |
| url | https://ogsh.abvpress.ru/jour/article/view/673 |
| work_keys_str_mv | AT porumyantsev personalizedtherapywithlenvatinibforprogressiveradioiodinerefractorydifferentiatedthyroidcancerinroutineclinicalpractice AT evborodavina personalizedtherapywithlenvatinibforprogressiveradioiodinerefractorydifferentiatedthyroidcancerinroutineclinicalpractice AT sikutukova personalizedtherapywithlenvatinibforprogressiveradioiodinerefractorydifferentiatedthyroidcancerinroutineclinicalpractice AT ebvasilyeva personalizedtherapywithlenvatinibforprogressiveradioiodinerefractorydifferentiatedthyroidcancerinroutineclinicalpractice |